Aardvark Therapeutics (NASDAQ:AARD) Cut to Sell at Wall Street Zen

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday.

Several other analysts have also commented on AARD. Morgan Stanley started coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They set an "overweight" rating and a $29.00 price target on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $50.00 price target on shares of Aardvark Therapeutics in a research report on Tuesday, April 1st. Bank of America lifted their price target on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. Finally, Royal Bank Of Canada reduced their price target on shares of Aardvark Therapeutics from $21.00 to $20.00 and set an "outperform" rating on the stock in a research report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $31.25.

Aardvark Therapeutics Price Performance

Shares of Aardvark Therapeutics stock traded up $0.42 on Friday, hitting $11.27. 70,848 shares of the company were exchanged, compared to its average volume of 22,720. The stock's 50-day moving average is $9.97. Aardvark Therapeutics has a 1-year low of $4.88 and a 1-year high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.01).

Institutional Trading of Aardvark Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Walleye Capital LLC purchased a new stake in Aardvark Therapeutics in the first quarter valued at approximately $88,000. Goldman Sachs Group Inc. purchased a new stake in Aardvark Therapeutics in the first quarter valued at approximately $153,000. Adage Capital Partners GP L.L.C. purchased a new stake in Aardvark Therapeutics in the first quarter valued at approximately $1,878,000. Braidwell LP purchased a new stake in Aardvark Therapeutics in the first quarter valued at approximately $3,755,000. Finally, Cormorant Asset Management LP purchased a new stake in Aardvark Therapeutics in the first quarter valued at approximately $6,009,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.